A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer.
Patrick M BolandJohn M L EbosKristopher AttwoodMichalis MastriChristos FountzilasRenuka V IyerChristopher BankerAndrew K L GoeyRobert BiesWen Wee MaMarwan G FakihPublished in: JNCI cancer spectrum (2024)
NCT02393755.